Health and Human Services Office of Inspector General has released their 2017 Work Plan. The updated work plan includes some new and revised audits and evaluations, as well as some older audits and evaluations that OIG continues to focus on. This article goes through many of the items focused on the drug and device world and discusses what compliance officers should do with this Work Plan.
For the life science compliance professional, the issuance of the Office of Inspector General’s (“OIG”) Annual Work Plan is a highly anticipated event. It offers a window for manufacturers, providers, and payers into the primary areas of concern for the Department of Health and Human Services (“HHS”) on both a programmatic and enforcement level. As we have seen over the years, some of the areas of concern reflect persistent and concerning vulnerabilities that OIG has highlighted many times. However, the annual Work Plan also includes new and emerging issues that HHS will face in the upcoming year – and beyond.
Read the full article in the January 2017 issue of Life Science Compliance Update.